Last reviewed · How we verify
GI148512
GI148512 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
GI148512 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | GI148512 |
|---|---|
| Also known as | Benzoyl Peroxide 3% Gel |
| Sponsor | GlaxoSmithKline |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Immunology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism reduces airway inflammation and mucus production, making it suitable for respiratory inflammatory conditions. The drug's selectivity for PDE4 aims to minimize systemic side effects associated with broader phosphodiesterase inhibition.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Nausea
- Diarrhea
- Headache
- Tremor
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GI148512 CI brief — competitive landscape report
- GI148512 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI